IP Library › Granted Patent US 12,281,174
Granted Patent B2
US 12,281,174 · App. 17/561,415 · Granted Apr 22, 2025

High-affinity anti-MERTK antibodies and uses thereof

Inventors: Masoud Tavazoie (New York, NY); Isabel Kurth (New York, NY); Shugaku Takeda (Queens Village, NY); Celia Andreu-Agullo (New York, NY); Ivo Lorenz (Brooklyn, NY)
Assignee: Inspirna, Inc.
C07K16/40A61K39/3955A61K47/65A61K47/6801A61P35/00C07K2317/24C07K2317/31C07K2317/54C07K2317/55C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,174
App. No.
17/561,415
Granted
Apr 22, 2025
Kind
B2
Abstract

The present disclosure provides antibodies (e.g., humanized antibodies) that specifically bind to Mer Tyrosine Kinase (MERTK; e.g., human MERTK) and compositions comprising such antibodies. The present disclosure also provides antibody-drug conjugates comprising (i) an anti-MERTK antibody or antigen-binding fragment thereof described herein that specifically binds to MERTK (e.g., human MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates. The present disclosure also provides methods for treating cancer, comprising administering to a human subject in need thereof (a) an anti-MERTK antibody that specifically binds to MERTK (e.g., human MERTK) or an antigen-binding fragment thereof described herein, or (b) an antibody-drug conjugate that comprises (i) an anti-MERTK antibody or antigen-binding fragment thereof that specifically binds to MERTK (e.g., human MERTK), and (ii) a cytotoxic agent conjugated directly to the antibody or conjugated to the antibody via a linker.

Claims (20)

1. An antibody-drug conjugate comprising an antibody moiety comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence of sequence of SEQ ID NO: 105 and the VL comprises the amino acid sequence of SEQ ID NO: 106, wherein the antibody moiety is conjugated to MMAE via an mc-vc-PABC linker, and wherein the antibody moiety is an immunoglobulin.

2. An antibody-drug conjugate comprising an antibody moiety comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence of sequence of SEQ ID NO: 105 and the VL comprises the amino acid sequence of SEQ ID NO: 106, wherein the antibody moiety is conjugated to SN-38 via the CL2A linker, and wherein the antibody moiety is an immunoglobulin.

3. The antibody-drug conjugate of claim 1 , wherein the immunoglobulin comprises a human constant region.

4. A method of treating a MERTK-expressing cancer in a human subject in need thereof, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of the antibody-drug conjugate of claim 1 , and a pharmaceutically acceptable carrier.

5. A method of treating a MERTK-expressing cancer in a human subject in need thereof, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of the antibody-drug conjugate of claim 3 , and a pharmaceutically acceptable carrier.

6. The method of claim 4 , wherein said MERTK-expressing cancer is a cancer of the head and neck, lung, breast, bone, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate or thyroid; or wherein said MERTK-expressing cancer is a melanoma, a sarcoma, a lymphoma, or a leukemia.

7. The method of claim 4 , wherein said MERTK-expressing cancer is a sarcoma, squamous cell carcinoma, melanoma, glioma, glioblastoma, neuroblastoma, Kaposi's sarcoma, gastric cancer, colorectal cancer, non-small cell lung carcinoma, head and neck cancer, or multiple myeloma.

8. The method of claim 4 , wherein said MERTK-expressing cancer is acute myelogenous leukemia or acute lymphocytic leukemia.

9. The method of claim 4 , wherein said MERTK-expressing cancer is breast cancer.

10. The method of claim 9 , wherein said MERTK-expressing cancer is triple-negative breast cancer.

11. The antibody-drug conjugate of claim 2 , wherein the immunoglobulin comprises a human constant region.

12. A method of treating a MERTK-expressing cancer in a human subject in need thereof, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of the antibody-drug conjugate of claim 2 , and a pharmaceutically acceptable carrier.

13. A method of treating a MERTK-expressing cancer in a human subject in need thereof, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of the antibody-drug conjugate of claim 11 , and a pharmaceutically acceptable carrier.

14. The method of claim 12 , wherein said MERTK-expressing cancer is a cancer of the head and neck, lung, breast, bone, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate or thyroid; or wherein said MERTK-expressing cancer is a melanoma, a sarcoma, a lymphoma, or a leukemia.

15. The method of claim 12 , wherein said MERTK-expressing cancer is a sarcoma, squamous cell carcinoma, melanoma, glioma, glioblastoma, neuroblastoma, Kaposi's sarcoma, gastric cancer, colorectal cancer, non-small cell lung carcinoma, head and neck cancer, or multiple myeloma.

16. The method of claim 12 , wherein said MERTK-expressing cancer is acute myelogenous leukemia or acute lymphocytic leukemia.

17. The method of claim 12 , wherein said MERTK-expressing cancer is breast cancer.

18. The method of claim 17 , wherein said MERTK-expressing cancer is triple-negative breast cancer.

19. A population of the antibody-drug conjugate of claim 1 , which has a drug-to-antibody ratio (DAR) between 1 to 12.

20. A population of the antibody-drug conjugate of claim 2 , which has a DAR between 1 to 12.

Continuity (3)
Continuation 16801078 · Feb 25, 2020
Provisional Application 62810841 · Feb 26, 2019
Related Publication 20220220222A1 · Jul 14, 2022
References Cited (88)
US 5122464A · Wilson et al. · 1992 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5766886A · Studnicka et al. · 1998 [cited by applicant]
US 5837242A · Holliger et al. · 1998 [cited by applicant]
US 5869620A · Whitlow et al. · 1999 [cited by applicant]
US 5989830A · Davis et al. · 1999 [cited by applicant]
US 6005079A · Casterman et al. · 1999 [cited by applicant]
US 6132992A · Ledbetter et al. · 2000 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 7183076B2 · Arathoon et al. · 2007 [cited by applicant]
US 7659241B2 · Senter et al. · 2010 [cited by applicant]
US 7829531B2 · Senter et al. · 2010 [cited by applicant]
US 7851437B2 · Senter et al. · 2010 [cited by applicant]
US 7951917B1 · Arathoon et al. · 2011 [cited by applicant]
US 8227577B2 · Klein et al. · 2012 [cited by applicant]
US 8541178B2 · Kaur et al. · 2013 [cited by applicant]
US 8586713B2 · Davis et al. · 2013 [cited by applicant]
US 10221248B2 · Tavazoie et al. · 2019 [cited by applicant]
US 11242407B2 · Tavazoie et al. · 2022 [cited by applicant]
US 11613588B2 · Tavazoie et al. · 2023 [cited by applicant]
US 20050042664A1 · Wu et al. · 2005 [cited by applicant]
US 20050048549A1 · Cao et al. · 2005 [cited by applicant]
US 20150291609A1 · Wang · 2015 [cited by examiner]
US 20180002444A1 · Tavazoie et al. · 2018 [cited by applicant]
US 20190241676A1 · Tavazoie et al. · 2019 [cited by applicant]
US 20200255543A1 · Tavazoie et al. · 2020 [cited by applicant]
US 20230146646A1 · Tavazoie et al. · 2023 [cited by applicant]
EP 239400 · 1987 [cited by applicant]
EP 519596 · 1992 [cited by applicant]
EP 592106 · 1994 [cited by applicant]
WO WO8605807 · 1986 [cited by applicant]
WO WO8901036 · 1989 [cited by applicant]
WO WO9317105 · 1993 [cited by applicant]
WO WO9404678 · 1994 [cited by applicant]
WO WO9425591 · 1994 [cited by applicant]
WO WO9109967 · 1997 [cited by applicant]
WO WO0144301 · 2001 [cited by applicant]
WO WO2016106221 · 2016 [cited by applicant]
WO WO2019005756 · 2019 [cited by applicant]
WO WO2020176497A1 · 2020 [cited by applicant]
WO WO2021119508A1 · 2021 [cited by applicant]
WO WO2021189053A1 · 2021 [cited by applicant]
WO WO2021202590A1 · 2021 [cited by applicant]
Perez et al. (Drug Discovery Today, 19(7): 869-881, 2014). [cited by examiner]
Marotti et al. (American Journal of Pathology, 187(10): 2133-2138, 2017). [cited by examiner]
International Search Report and Written Opinion of the International Searching Authority, dated Aug. 10, 2020, for corresponding PCT Application No. PCT/US2020/019690, filed Feb. 25, 2020 (17 pages). [cited by applicant]
Ausubel et al., eds, 1989, Current Protocols in Molecular Biology, vol. I, Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York:6.3.1-6.3.6 and 2.10.3. [cited by applicant]
Baca et al., 1997, “Antibody Humanization Using Monovalent Phage Display”, J Biol Chem, 272(16):10678-10684. [cited by applicant]
Beck et al., 2017, “Strategies and challenges for the next generation of antibody-drug conjugates”, Nat Rev Drug Discov, 16(5):315-337. [cited by applicant]
Caldas et al., 2000, “Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen”, Protein Eng, 13(5):353-360. [cited by applicant]
Cannarile et al., “Colony-stimulating factor 1 receptor (CSFIR) inhibitors in cancer therapy,” J Immunother Cancer. Jul. 18, 2017;5(1):53. [cited by applicant]
Cardillo et al., 2011, “Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys”, Clin Cancer Res, 17(10):3157-31… [cited by applicant]
Clackson et al., 1991, “Making antibody fragments using phage display libraries”, Nature, 352(6336):624-628. [cited by applicant]
Cockett et al., 1990, “High Level Expression of Tissue Inhibitor of Metalloproteinases in Chinese Hamster Ovary Cells Using Glutamine Synthetase Gene Amplification”, Biotechnology, 8(7):662-667. [cited by applicant]
Cook et al., 2013, “MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis”, J Clin Invest, 123(8):3231-3242. [cited by applicant]
Couto et al., 1995, “Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization”, Cancer Res, 55(8):1717-1722. [cited by applicant]
Couto et al., 1995, “Designing Human Consensus Antibodies with Minimal Positional Templates”, Cancer Res, 55(23 Suppl):5973s-5977s. [cited by applicant]
Crittenden et al., 2016, “Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy”, Oncotarget, 7(48):78653-78666. [cited by applicant]
Cummings et al., 2013, “Molecular Pathways: MERTK Signaling in Cancer”, Clin Cancer Res, 19(19):5275-5280. [cited by applicant]
Foecking and Hofstetter, 1986, “Powerful and versatile enhancer-promoter unit for mammalian expression vectors”, Gene, 45(1):101-105. [cited by applicant]
Goldenberg et al., 2018, “The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target”, Oncotarget, 9(48):28989-29006. [cited by applicant]
Jackson, 2016, “Processes for Constructing Homogeneous Antibody Drug Conjugates”, Org Process Res Dev, 20(5):852-866. [cited by applicant]
Kim and Hong, 2007, “Guided selection of human antibody light chains against TAG-72 using a phage display chain shuffling approach”, J Microbiol, 45(6):572-577. [cited by applicant]
Kutmeier et al., 1994, “Assembly of humanized antibody genes from synthetic oligonucleotides using a single-round PCR”, BioTechniques, 17(2):242-246. [cited by applicant]
Linger et al., 2013, “Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer”, Oncogene, 32(29):3420-3431. [cited by applicant]
Liu et al., 2013, “UNC1062, a new and potent Mer inhibitor”, Eur J Med Chem, 65:83-93. [cited by applicant]
McCombs and Owen, 2015, “Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry”, AAPS J, 17(2):339-351. [cited by applicant]
Minn et al., 2005, “Genes That Mediate Breast Cancer Metastasis to Lung”, Nature, 436(7050):518-524. [cited by applicant]
Morea et al., 2000, “Antibody modeling: Implications for engineering and design”, Methods, 20(3):267-279. [cited by applicant]
Muyldermans, 2001, “Single Domain Camel Antibodies: Current Status”, J Biotechnol, 74(4):277-302. [cited by applicant]
Nuttall et al., 2000, “Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents”, Curr Pharm Biotehnol, 1(3):253-263. [cited by applicant]
Padlan,1991, “A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties”, Mol Immunol, 28(4/5):489-498. [cited by applicant]
Pedersen et al., 1994, “Comparison of Surface Accessible Residues in Human and Murine Immunoglobulin Fv Domains. Implication for Humanization of Murine Antibodies”, J Mol Biol, 235(3):959-973. [cited by applicant]
Peters and Brown, 2015, “Antibody-drug conjugates as novel anti-cancer chemotherapeutics”, Biosci Rep, 35(4):art:e00225. [cited by applicant]
Png et al., 2012, “A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells”, Nature, 481(7380):190-194. [cited by applicant]
Rader et al., 1998, “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries”, Proc Natl Acad Sci USA, 95(15):8910-8915. [cited by applicant]
Riechmann and Muyldermans, 1999, “Single Domain Antibodies: Comparison of Camel VH and Camelised Human VH Domains”, J Immunol, 231:25-38. [cited by applicant]
Roguska et al., 1994, “Humanization of murine monoclonal antibodies through variable domain resurfacing”, Proc Natl Acad Sci USA, 91(3):969-973. [cited by applicant]
Roguska et al., 1996, “A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing”, Protein Eng, 9(10):895-904. [cited by applicant]
Sandhu, 1994, “A rapid procedure for the humanization of monoclonal antibodies”, Gene, 150(2):409-410. [cited by applicant]
Sather et al., 2007, “A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation”, Blood, 109(3):1026-1033. [cited by applicant]
Studnicka et al., 1994, “Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues.”, Prot Engineering, 7(6):805-814. [cited by applicant]
Tan et al., 2002, ““Superhumanized” Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28”, J Immunol, 169:1119-1125. [cited by applicant]
Verma et al., 2011, “Targeting Axl and Mer Kinases in Cancer, ”Mol Cancer Ther, 10(10):1763-1773. [cited by applicant]
Zizzo et al., 2012, “Efficient Clearance of Early Apoptotic Cells by Human Macrophages Requires M2c Polarization and MerTK Induction”, J Immunology, 189(7):3508-3520. [cited by applicant]